Entellus Medical (ENTL) Tops Q2 EPS by 8c; Guides FY16 Revenue
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Entellus Medical Announces Second Quarter 2016 Financial Results
August 3, 2016 4:03 PM EDTPLYMOUTH, Minn., Aug. 03, 2016 (GLOBE NEWSWIRE) -- Entellus Medical, Inc. (the Company or Entellus Medical) (NASDAQ: ENTL), a medical technology company focused on delivering superior patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis patients, today reported its financial results for the quarter ended June 30, 2016.
Recent Highlights and Accomplishments
Revenue of $18.7 million in the second quarter of 2016, an increase of 23% year-over-yearAchieved balanced revenue growth across ear, nose and throat (ENT) offices and ORs In-Office revenue represented 57% of U.S.... More